Tuvusertib

also known as M1774 · MSC2584415A · VRT-1363004 · VXc-400

Small molecule targets ATR via inhibition

Developed for: cancer · cancer of unknown primary site · metastatic malignant neoplasm · astrocytoma (excluding glioblastoma) · breast cancer · castration-resistant prostate carcinoma · colorectal carcinoma · cutaneous neuroendocrine carcinoma
+11 more
· endometrial carcinoma · endometrial clear cell adenocarcinoma · endometrial endometrioid adenocarcinoma · hematopoietic and lymphoid system neoplasm · neoplasm · non-small cell lung carcinoma · ovarian carcinoma · ovarian clear cell adenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian serous adenocarcinoma · urothelial carcinoma
Investigated by: Merck KGaA, Darmstadt, Germany · EMD Serono Research & Development Institute, Inc. · National Cancer Institute (NCI) · EMD Serono · Grupo Español de Investigación en Neurooncología · Institut Curie
+8 more
· Institut Paoli-Calmettes · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Merck Sharp & Dohme LLC · NRG Oncology · National Cancer Institute, France · Panagiotis Konstantinopoulos, MD, PhD · ProLynx LLC · The Applebaum Foundation

Trials 16 · a red edge is where a trial was stopped

today NCT07417761 · Ph 2 NCT06337630 · Ph 1 NCT06518564 · Ph 2 NCT06433219 · Ph 2 NCT06424717 · Ph 2 NCT06421935 · Ph 1 NCT05687136 · Ph 1 NCT05947500 · Ph 2 NCT05986071 · Ph 1/2 NCT06308263 · Ph 1 NCT05950464 · Ph 1 NCT05828082 · Ph 2 NCT05691491 · Ph 1/2 NCT05882734 · Ph 1/2 NCT05396833 · Ph 1 NCT04170153 · Ph 1

202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT06337630	Jan → Nov 2025	cancer	Institut Curie	Terminated	No outcome recorded
Phase 1	NCT06421935	Aug 2024 → Feb 2027 expected	neoplasm	EMD Serono Research & Development Institute, Inc.	Active not recruiting	No outcome recorded
Phase 1	NCT05687136	Jun 2024 → Aug 2026 overdue	metastatic malignant neoplasm	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1	NCT06308263	Mar 2024 → Apr 2026	cancer	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 1	NCT05950464	Dec 2023 → Jun 2027 expected	endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma +1	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1	NCT05396833	Jun 2022 → Jan 2027 expected	cancer of unknown primary site	EMD Serono Research & Development Institute, Inc.	Active not recruiting	No outcome recorded
Phase 1	NCT04170153	Dec 2019 → Jul 2026 overdue	cancer of unknown primary site	EMD Serono Research & Development Institute, Inc.	Active not recruiting	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT05986071	May 2024 → Apr 2027 expected	breast cancer	Institut Paoli-Calmettes	Not yet recruiting	No outcome recorded
Phase 1/2	NCT05691491	Sep 2023 → Mar 2027 expected	colorectal carcinoma, hematopoietic and lymphoid system neoplasm, metastatic malignant neoplasm	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1/2	NCT05882734	Sep 2023 → Sep 2026 expected	non-small cell lung carcinoma	EMD Serono Research & Development Institute, Inc.	Active not recruiting	No outcome recorded
Phase 26 trials
Phase 2	NCT07417761	Dec 2025 → Sep 2028 expected	astrocytoma (excluding glioblastoma)	Grupo Español de Investigación en Neurooncología	Recruiting	No outcome recorded
Phase 2	NCT06518564	Nov 2024 → Aug 2027 expected	endometrial carcinoma	Panagiotis Konstantinopoulos, MD, PhD	Recruiting	No outcome recorded
Phase 2	NCT06433219	Oct 2024 → Jun 2026 overdue	ovarian carcinoma	EMD Serono Research & Development Institute, Inc.	Active not recruiting	No outcome recorded
Phase 2	NCT06424717	Aug 2024 → Jan 2026	urothelial carcinoma	EMD Serono Research & Development Institute, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT05947500	May 2024 → Jan 2028 expected	cutaneous neuroendocrine carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT05828082	Oct 2023 → Jan 2027 expected	castration-resistant prostate carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	Tuvusertib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05828082 ↗ 11 NCT05691491 ↗ NCT05950464 ↗ NCT05687136 ↗ NCT06433219 ↗ NCT07417761 ↗ NCT06308263 ↗ NCT06424717 ↗ NCT05396833 ↗ NCT05947500 ↗ NCT06337630 ↗ NCT06421935 ↗
Known as	M1774	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06518564 ↗ 3 NCT04170153 ↗ NCT05986071 ↗ NCT05882734 ↗
Known as	MSC2584415A	“M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗
Known as	VRT-1363004	“M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗
Known as	VXc-400	“M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗
Action	Inhibit	“ATR Inhibitor Tuvusertib” NCT05396833 ↗
Modality	Small molecule	“M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗ 1 CHEMBL5314933 ↗
Route	Oral	“M1774 will be administered orally throughout the study.” NCT04170153 ↗
Target	ATR	“ATR Inhibitor Tuvusertib” NCT05396833 ↗